


ETCTN Trials by Disease/Treatment Area: Leukemia



NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide.

ETCTN Leukemia Trials (Open as of 4/15/2026)

| Protocol Number | Phase | Protocol Title |
|-----------------|-------|--|
| 10335 | I | A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL) |
| 10237 | I | A Phase 1 Study of MLN7243 (TAK-243) for Either Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia Refractory to Hypomethylating Agents |
| 10538 | II | Venetoclax In Combination with ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 Trial |
| 10596 | Ib | A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL Rearranged Disease |
| 10637 | II | Phase 2 Trial of Venetoclax in Classic or Variant Hairy Cell Leukemia |
| 10653 | I | A phase I study of Lintuzumab-Ac-225 in combination with venetoclax and ASTX-727 in adults with newly diagnosed AML |
| 10630 | I | Phase 1 Trial of Iadademstat in Combination with Venetoclax and Azacitidine in Patients with Treatment Naïve AML |
| 10674 | I | A phase I study evaluating the safety of Cirtuvivint as monotherapy and in combination with ASTX727 and ASTX727 + venetoclax in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) |
| 10675 | II | A Randomized Phase II Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs) |
| 10664 | Ib/II | Phase 1b/2 Study of Combination Tovorafenib and Rituximab Treatment in Classical Hairy Cell Leukemia |
| 10695 | I | Lintuzumab-Ac225 monotherapy for patients with hypomethylating agent-refractory myelodysplastic syndrome |
| 10708 | Pilot | A Phase 2 Pilot Study of Mirdametinib in Relapsed Refractory Chronic Lymphocytic Leukemia |